信会师报字[2025]第ZA12088号 东富龙科技集团股份有限公司 募集资金存放与使用情况专项 报告的鉴证报告 2024 年度 关于东富龙科技集团股份有限公司2024年度募集资金存放 与使用情况 专项报告的鉴证报告 东富龙科技集团股份有限公司全体股东： 我们接受委托，对后附的东富龙科技集团股份有限公司（以下简 称"贵公司"） 2024年度募集资金存放与使用情况专项报告（以下简 称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 东富龙科技集团股份有限公司董事会的责任是按照中国证券监 督管理委员会《上市公司监管指引第2号——上市公司募集资金管理 和使用的监管要求（2022年修订）》（证监会公告〔2022〕15号）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》以及《深圳证券交易所创业板上市公司自律监管指南第2 号——公告格式》的相关规定编制募集资金专项报告。这种责任包括 设计、执行和维护与募集资金专项报告编制相关的内部控制，确保募 集资金专项报告真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募 ...

中信证券股份有限公司 关于东富龙科技集团股份有限公司 2024 年度内部控制自我评价报告的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为东富龙科技集 团股份有限公司（以下简称"东富龙"或"公司"）持续督导工作的保荐人，根据《证 券发行上市保荐业务管理办法》、《上市公司监管指引第2号——上市公司募集资金管 理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》等有关法律法规和规范性文 件的要求，对《东富龙科技集团股份有限公司2024年度内部控制自我评价报告》进行 了核查，具体情况如下： 一、内部控制评价工作情况 公司内部控制评价工作由董事会审计委员会领导，由公司内部审计部具体负责实 施，围绕公司内部环境、风险评估、控制活动、信息与沟通、内部监督等要素，对公 司内部控制设计与运行情况进行全面评价。 （一）内部控制评价范围 公司根据基本规范及相关配套指引的要求，从公司的各项业务规模和实际经营情 况出发，以风险为导向，结合公司年度合并财务报表数据，确定纳入评价范围的主要 单位、业务和事项以及高风险领域。 1、纳入评价范围 ...

东富龙科技集团股份有限公司 审计报告及财务报表 二○二四年度 东富龙科技集团股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动 | 9-13 | | | 表 | | | | 财务报表附注 | 1-160 | 审计报告 信会师报字[2025]第 12087 号 东富龙科技集团股份有限公司全体股东： 一、 审计意见 我们审计了东富龙科技集团股份有限公司（以下简称东富龙科技） 财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 1,137,333,804.93, representing a 2.58% increase compared to CNY 1,108,769,112.04 in the same period last year[3] - Net profit attributable to shareholders decreased by 68.87% to CNY 20,132,627.86 from CNY 64,664,107.55 year-on-year[3] - Basic and diluted earnings per share fell by 69.06% to CNY 0.0263 from CNY 0.0850 in the same period last year[3] - Net profit for the current period was ¥16,747,787.39, a decrease of 75.7% from ¥68,109,786.32 in the previous period[22] - Earnings per share (basic and diluted) decreased to ¥0.0263 from ¥0.0850 in the previous period[22] Cash Flow - The net cash flow from operating activities was negative at CNY -9,002,449.29, a decline of 104.45% compared to CNY 202,163,954.16 in the previous year[3] - Cash flow from operating activities was ¥1,219,995,336.64, slightly down from ¥1,230,057,666.15 in the previous period[24] - The net cash flow from operating activities was -$9,002,449.29, a significant decrease compared to $202,163,954.16 in the previous period[25] - Cash inflow from investment activities totaled $1,091,994,741.82, up from $557,875,254.77 year-over-year[25] - The net cash flow from financing activities was $15,490,509.21, contrasting with a negative cash flow of -$13,441,839.14 in the prior period[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,027,382,309.59, a slight decrease of 0.31% from CNY 13,068,340,218.01 at the end of the previous year[3] - Total liabilities decreased to ¥4,961,901,070.28 from ¥5,021,635,990.29 in the previous period[20] - Total equity increased to ¥8,065,481,239.31 from ¥8,046,704,227.72 in the previous period[20] - The total non-current assets include fixed assets valued at CNY 1,906,487,367.99, up from CNY 1,642,245,216.99, reflecting a growth of approximately 16.1%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 31,365[12] - The top ten shareholders include significant holdings by Zheng Keqing (125,667,408 shares) and Zheng Xiaodong (65,239,752 shares), indicating a concentration of ownership[14] - The company has a repurchase account holding 4,980,001 shares, accounting for 0.65% of the total share capital[15] - The company has a total of 203,170,685.00 shares under lock-up due to executive restrictions, which will be released at a rate of 25% annually during their tenure[16] Operational Costs and Expenses - Total operating costs increased to ¥1,124,874,650.63, up 10.0% from ¥1,022,134,287.29 in the previous period[21] - Research and development expenses rose to ¥79,354,495.69, compared to ¥74,143,815.40 in the previous period, reflecting a focus on innovation[21] Tax and Other Financial Metrics - The company experienced a 39.14% increase in taxes and surcharges, mainly due to higher property tax payments compared to the previous year[9] - The company reported a significant increase in contract liabilities to ¥3,435,594,875.20, up from ¥3,296,488,231.32 in the previous period, indicating growth in future revenue commitments[21] - The company received tax refunds amounting to $12,925,948.18, compared to $1,869,373.30 previously[25] Cash and Equivalents - Cash and cash equivalents increased to CNY 2,718,161,234.59 from CNY 2,509,611,665.21, representing a growth of about 8.3%[18] - The total cash and cash equivalents at the end of the period reached $2,666,234,489.71, an increase from $2,291,987,781.86[25] - The net increase in cash and cash equivalents for the period was $198,362,266.57, compared to $19,709,451.57 in the prior period[25]

Financial Performance - The company achieved operating revenue of CNY 5.01 billion, a decrease of 11.19% compared to the same period last year[7]. - The net profit attributable to shareholders was CNY 194 million, down 67.66% year-on-year, primarily due to a slowdown in fixed asset investment in the domestic biopharmaceutical industry[7]. - The comprehensive gross profit margin declined compared to the previous year, attributed to intensified competition in the pharmaceutical equipment industry[7]. - The company's operating revenue for 2024 was CNY 5,010,142,452, representing a decrease of 11.19% compared to CNY 5,641,696,443 in 2023[5]. - The net profit attributable to shareholders for 2024 was CNY 194,093,221, a significant decline of 67.66% from CNY 600,237,388 in 2023[5]. - The basic earnings per share for 2024 was CNY 0.26, down 67.09% from CNY 0.79 in 2023[5]. - The company reported a negative net profit of CNY 17,276,948.36 in the fourth quarter of 2024, after deducting non-recurring gains and losses[25]. - The company reported a total investment income of ¥13,332,470.30, contributing 5.87% to total profit[77]. - The company reported a net profit of 289,825,700.76 CNY for the period, with a significant decrease compared to the previous year[103]. Profit Distribution - The profit distribution plan approved by the board is to distribute a cash dividend of CNY 0.76 per 10 shares (including tax) to all shareholders[10]. - The company plans to distribute cash dividends of 2.4 RMB per 10 shares, totaling 182,306,313.36 RMB (including tax) based on a total share capital of 759,609,639 shares[172]. - The company's profit distribution plan for 2024 proposes a cash dividend of 0.76 RMB per 10 shares, totaling 57,824,450.96 RMB (including tax)[176]. Market Strategy and Competition - The company aims to strengthen penetration into high-quality customer groups and adjust its market competition strategy to stabilize and expand market share[7]. - The company is adapting its market competition strategy to stabilize and expand its market share amidst increasing competition in the pharmaceutical equipment industry[52]. - The company is actively pursuing international market expansion to enhance its brand recognition and market share amid increasing domestic competition[37]. - The company is focusing on mergers and acquisitions to enhance its technological capabilities and market share[1]. - The company is addressing industry competition risks by supporting systematic construction in various fields, including injection drugs and biopharmaceuticals[114]. Research and Development - The company has a strong research and development capability, having developed advanced process equipment with independent intellectual property rights[49]. - Research and development expenses totaled ¥346.29 million, a decrease of 8.76% from ¥379.53 million in 2023[67]. - The company reported a research and development investment of ¥346,288,192.44 in 2024, representing 6.91% of operating revenue, an increase from 6.73% in 2023[74]. - The company is focusing on enhancing its product innovation capabilities and aims to provide differentiated competitive advantages by integrating cutting-edge technologies[53]. - The company is currently developing a new product line that is expected to generate an additional $50 million in revenue annually[1]. Operational Efficiency - The cash flow from operating activities increased by 371.84% to CNY 880,608,714 in 2024, compared to CNY 247,153,989 in 2023[5]. - The company aims to improve operational efficiency by 10% through new automation technologies[1]. - The company is committed to maintaining production flexibility to adapt to market demand fluctuations and enhance customer satisfaction[115]. - The company is focusing on post-investment management to minimize investment impairment risks associated with mergers and acquisitions[118]. Corporate Governance - The company emphasizes maintaining independence from its controlling shareholder in business, personnel, assets, and finance[130]. - The company is committed to improving its internal control system and corporate governance structure to enhance operational standards[126]. - The company has established a monitoring and early warning mechanism for market value management to ensure compliance and effectiveness[121]. - The company has a clear governance structure with defined roles for its board members, enhancing accountability and oversight[135]. - The company has implemented a stock incentive plan, with significant share increases for key executives, indicating a focus on aligning management interests with shareholder value[134]. Investment and Acquisitions - The company plans to invest 53,000 million in the development of new biopharmaceutical equipment by 2026, aiming for a significant market expansion[92]. - The company is actively pursuing market expansion strategies, with a focus on increasing its presence in the biopharmaceutical sector[92]. - The company has completed the acquisition of a medical technology firm for 3,000 million, which is expected to enhance its product offerings[92]. - The company is committed to a strategic investment of 4,895 million in expanding its operational capabilities through mergers and acquisitions[92]. Sustainability and Social Responsibility - The company is committed to green manufacturing practices, utilizing eco-friendly materials and energy-saving technologies to minimize environmental impact[39]. - The management team emphasized the importance of sustainability initiatives, aiming to reduce operational costs by 5% through eco-friendly practices[149]. - The company has implemented measures to reduce carbon emissions, although specific details were not disclosed[198]. - Employees receive comprehensive social security benefits and welfare, including full insurance coverage from the first month of employment[200]. Employee Engagement and Training - The company has implemented a comprehensive training program, conducting over 100 training sessions annually and offering nearly 1,000 online courses[170]. - The total number of employees at the end of the reporting period was 5,417, with 1,991 in the parent company and 3,426 in major subsidiaries[166]. - The company has established a competitive and fair compensation system to attract and retain talent, integrating performance evaluation and career development[168]. Future Outlook - The company plans to expand global marketing efforts and improve service capabilities to secure high-quality orders[113]. - The company has set a performance guidance of 15% revenue growth for the next fiscal year[1]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20% to 1.8 billion yuan[149].

证券代码：300171 证券简称：东富龙 公告编号：2025-008 东富龙科技集团股份有限公司（以下简称"公司"）于 2025 年 1 月 27 日召开 第六届董事会第十六次（临时）会议，审议通过《关于与专业机构共同投资设立 上海生物医药并购基金暨关联交易的议案》，董事会同意公司作为有限合伙人以 自有资金认缴出资 20,000 万元，与其他专业机构共同出资设立上海生物医药并 购私募基金合伙企业（有限合伙）（工商核定名，以下简称"标的基金"、"并购基 金"或"基金"）。 具体内容详见公司于 2025 年 1 月 28 日在巨潮资讯网披露的《关于与专业机 构共同投资设立上海生物医药并购基金暨关联交易的公告》（公告编号：2025- 007）。 二、基金进展情况 （一）交易各方情况 2025 年 3 月 26 日，公司与关联方上海上实资本管理有限公司、上海上实生 物医药管理咨询有限公司等 13 方合伙人签订《上海生物医药并购私募基金合伙 企业（有限合伙）有限合伙协议》。根据各方签署的合伙协议，标的基金完成了 工商设立手续。 东富龙科技集团股份有限公司 关于与专业机构共同投资设立的上海生物医药并购基金 完成私募投资基 ...

证券代码：300171 证券简称：东富龙 公告编号：2025-005 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）第六届董事会第十六次 （临时）会议于 2025 年 1 月 23 日以电话、书面方式通知各位董事，会议于 2024 年 1 月 27 日（星期一）以通讯表决方式召开。本次董事会会议应出席的董事 9 名，实际出席会议的董事 9 名。本次董事会会议由董事长郑效东先生主持，董事 会秘书王艳女士列席了本次会议。会议的召开符合《中华人民共和国公司法》及 《公司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《关于与专业机构共同投资设立上海生物医药并购基金暨关 联交易的议案》 为促进公司长远发展，充分借助专业投资机构的资源优势，进一步完善制药 装备赛道的产业布局，实现产业链引领、带动和贯通作用，在不影响公司日常经 营和发展、有效控制投资风险的前提下，董事会同意公司作为有限合伙人以自有 资金认缴出资 20,000 万元，与其他专业机构共同出资设立上海生物医药并购股 权投资合伙企业（有限合伙）（暂定 ...

证券代码：300171 证券简称：东富龙 公告编号：2025-006 东富龙科技集团股份有限公司（以下简称"公司"）第六届监事会第十四次 （临时）会议于 2025 年 1 月 23 日以电话、书面方式通知各位监事，会议于 2025 年 1 月 27 日（星期一）以通讯表决方式召开。本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。会议由监事会主席杨东生先生主持，董事会秘书 王艳女士列席了本次监事会。会议的召开符合《中华人民共和国公司法》及《公 司章程》的有关规定。会议经认真审议，通过如下议案： 一、审议通过《关于与专业机构共同投资设立上海生物医药并购基金暨关 联交易的议案》 本次交易决策程序符合《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章 程》等有关法律法规的规定，不存在损害公司及全体股东利益的情况。因此，监 事会一致同意公司与专业机构共同投资暨关联交易的事项。 投票结果：赞成票，3 票，占出席会议监事的 100%；反对票，0 票，占出席 会议监事的 0%；弃权票，0 票，占出席会议监事的 0%。 《关于与专业机构共同 ...

2、投资规模：全体合伙人拟认缴出资额为人民币 501,000 万元，公司拟作 为有限合伙人以自有资金认缴出资 20,000 万元，占出资总额的 3.99%。 3、投资目的：国家出台《关于深化上市公司并购重组市场改革的意见》等 系列政策，多措并举推动并购重组、促进企业做优做强，以上市公司高质量发展 带动经济高质量发展。公司作为上海市生物医药行业优质"链主"企业，参与组 建设立生物医药并购基金，对本市生物医药产业及公司未来的高质量发展极具战 略意义。标的基金将成为促进产业链集聚整合、推动产业转型升级、拓宽资本退 出通道的重要工具，可为上海加快打造全球生物医药研发经济和产业化高地提供 重要支撑。 4、公司董事刘大伟先生在上实资本担任董事兼副总裁，并拟于并购基金管 理公司设立完成后担任该主体董事兼总裁，根据《深圳证券交易所创业板股票上 市规则》和《公司章程》等相关规定，上实资本为公司关联方，并购基金管理公 司设立完成后为公司关联方（最终以工商登记注册结果为准）。本次交易构成关 联交易，但不构成《上市公司重大资产重组管理办法》规定的重大资产重组，本 次交易事项在董事会审批权限内，无需提交公司股东大会审议。 5、基金尚处 ...

中信证券股份有限公司 关于东富龙科技集团股份有限公司 与专业机构共同投资设立上海生物医药并购基金 暨关联交易的核查意见 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》《深圳证券交易所上市公司自律监管指引第7号——交易与关联交易》等 相关法律、法规和规范性文件的规定，中信证券股份有限公司（以下简称"保荐 机构"）作为东富龙科技集团股份有限公司（以下简称"东富龙"或"公司"） 2022年度向特定对象发行A股股票的保荐机构，对公司与专业机构共同投资设立 上海生物医药并购股权投资合伙企业（有限合伙）（暂定名，最终以工商登记核 准的名称为准，以下简称"上海生物医药并购基金"、"合伙企业"或"基金"） 暨关联交易的事项进行了审慎核查，具体内容如下： 一、东富龙与专业机构共同投资暨关联交易的概述 （一）交易基本情况 东富龙为促进公司长远发展，充分借助专业投资机构的资源优势，进一步完 善制药装备赛道的产业布局，实现产业链引领、带动和贯通作用，在不影响公司 日常经营和发展、有效控制投资风险的前提下，东富龙拟与上海国投先导生物医 ...